Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies derived from induced pluripotent stem cells (iPSC) — engineered NK cells and T cells designed as off-the-shelf alternatives to autologous CAR-T therapies like Kymriah and Yescarta. The leading candidates include FT522 (CAR-NK for B-cell lymphoma and autoimmunity) and FT836 (CAR-T for tumors). The iPSC platform theoretically allows allogeneic (donor-independent) treatment at a fraction of CAR-T costs.

The market hates this stock because Fate's 2023 collaboration with Janssen (Johnson and Johnson) was terminated, the FT-538 program was paused, and the company has restructured twice. Trailing EPS minus 1.09, P/B 1.14, market cap 204 million USD. The market has effectively priced the equity as cash-floor — meaning if the company runs out of cash without a partner, equity goes to zero.

Founder and former CEO Scott Wolchko stepped down in 2024. RA Capital Management (life-sciences fund) had a position. Insider activity has been minimal in recent years.

Standard valuation does not apply. Negative earnings, EV/Sales 16.9 on tiny revenue, market cap roughly equals cash. The stock is an option: if any of the three programs reads out positively in 2026, multi-bagger; if cash runs out before readout, equity wipeout via dilutive financing.

1. :
2. :
3. :

FATE is a clinical-stage biotech option with a cash-floor characteristic. I only want exposure to high-risk biotech through a diversified basket of 15 to 20 names; FATE belongs in that basket as a 0.2 to 0.4 percent position. The autoimmunity angle is the interesting wildcard — if iPSC-derived NK cells work in autoimmunity, the market is multiples of oncology. Risk is cash runs out before readout; reward is takeout or multi-bagger.